Last reviewed · How we verify
AX251 LAI 135 mg
At a glance
| Generic name | AX251 LAI 135 mg |
|---|---|
| Sponsor | Anxo Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AX251 LAI 135 mg CI brief — competitive landscape report
- AX251 LAI 135 mg updates RSS · CI watch RSS
- Anxo Pharmaceutical Co., Ltd. portfolio CI